Compare VFF & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VFF | AGEN |
|---|---|---|
| Founded | 1989 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.2M | 274.8M |
| IPO Year | 2013 | 1999 |
| Metric | VFF | AGEN |
|---|---|---|
| Price | $2.91 | $7.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 1.2M | ★ 1.4M |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 184.38 | 100.00 |
| EPS | 0.08 | ★ 0.96 |
| Revenue | ★ $215,937,000.00 | $42,877,086.00 |
| Revenue This Year | $12.19 | $107.63 |
| Revenue Next Year | $15.82 | N/A |
| P/E Ratio | $35.75 | ★ $8.14 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $1.81 | $2.71 |
| 52 Week High | $4.99 | $8.85 |
| Indicator | VFF | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 76.55 | 57.42 |
| Support Level | $2.75 | $2.97 |
| Resistance Level | $2.94 | $8.76 |
| Average True Range (ATR) | 0.13 | 0.58 |
| MACD | 0.04 | -0.07 |
| Stochastic Oscillator | 86.82 | 60.69 |
Village Farms International Inc owns and operates intensive agricultural greenhouse facilities in British Columbia and Texas, where it produces, markets and sells tomatoes, bell peppers and cucumbers. Its wholly owned subsidiary, Pure Sunfarms, is a vertically integrated licensed producer and supplier of cannabis products sold to other licensed providers and provincial governments across Canada and internationally. The Company's wholly owned subsidiary, Balanced Health, develops and sells, cannabidiol (CBD) based products including ingestible, edible and topical applications. The operating segments of the Company are VF Fresh (Produce), Cannabis Canada, Cannabis U.S., Clean Energy, and Cannabis - Netherlands. The company makes majority of its revenue from the Cannabis Canada segment.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.